Microbiome NewsFor decades, “bacteria as medicine” lived in a regulatory grey zone — somewhere between a supplement, a transplant and an experiment. Two FDA approvals, five months apart, ended that ambiguity.
On November 30, 2022, the agency approved Rebyota (fecal microbiota, live-jslm), made by Ferring Pharmaceuticals — the first-ever FDA-approved fecal microbiota product. Then on April 26, 2023, it approved Vowst (fecal microbiota spores, live-brpk; formerly SER-109) from Seres Therapeutics and Nestlé Health Science — the first orally administered fecal microbiota product. A treatment derived from screened human donor stool, in a capsule you swallow.
Both are cleared for the same job: preventing the recurrence of Clostridioides difficile infection in adults after they’ve completed antibiotics for recurrent CDI. That’s a brutal, common problem — antibiotics knock back C. diff but also flatten the surrounding community that would normally keep it in check, so it roars back. The therapy works by doing what a supplement never could at scale: restoring a whole microbial community.
Why this is a turning point
The science of fecal transplants is old; the regulation is what’s new. By granting full approval, the FDA recognised a defined, manufactured, quality-controlled microbiome product as a drug — with the donor screening, consistency and safety oversight that label implies.
The headline isn’t “poop pills.” It’s that a living microbial community can now clear the same bar as any other medicine.
That precedent matters far beyond C. diff. It establishes the manufacturing and evidence path that every future live biotherapeutic — for other infections, for metabolic disease, for the immune system — will follow.